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Abstract
Background: Crack cocaine use is known to contribute to poor adherence to antiretroviral medications; however,
little is known about facilitators of or barriers to effective HIV treatment use among HIV-infected crack cocaine
users. We sought to identify correlates of optimal pharmacy refill adherence for antiretroviral medications and
plasma HIV RNA viral load (pVL) suppression among this population.
Methods: Data from a prospective cohort of HIV-positive people who use illicit drugs in Vancouver, Canada, were
linked to comprehensive HIV clinical monitoring and pharmacy dispensation records. We used multivariable
generalized linear mixed-effects modelling to longitudinally identify factors associated with ≥95 % adherence to
pharmacy refills for antiretroviral medications and pVL <50 copies/mL among crack cocaine users exposed to
highly-active antiretroviral therapy (HAART).
Results: Among 438 HAART-exposed crack cocaine users between 2005 and 2013, 240 (54.8 %) had ≥95 %
pharmacy refill adherence in the previous 6 months at baseline. In multivariable analyses, homelessness (adjusted
odds ratio [AOR]: 0.58), ≥daily crack cocaine smoking (AOR: 0.64), and ≥ daily heroin use (AOR: 0.43) were
independently associated with optimal pharmacy refill adherence (all p < 0.05). The results for pVL non-detectability
were consistent with those of medication adherence, except that longer history of HAART (AOR: 1.06), receiving a
single tablet-per-day regimen (AOR: 3.02) and participation in opioid substitution therapies was independently
associated with pVL non-detectability (AOR: 1.55) (all p < 0.05).
Conclusions: Homelessness, and daily crack cocaine and/or heroin use were independently and negatively
associated with optimal HAART-related outcomes. With the exception of opioid substitution therapies, no addiction
treatment modalities assessed appeared to facilitate medication adherence or viral suppression. Evidence-based
treatment options for crack cocaine use that also confer benefits to HAART need to be developed.
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Background
Highly-active antiretroviral therapy (HAART) has sub-
stantially improved the life expectancy of people living
with HIV [1] and has also been shown to prevent HIV
transmission by reducing individuals’ viral load to un-
detectable levels [2, 3]. Despite the remarkable impact of
HAART on the HIV/AIDS pandemic, its benefits on dis-
ease progression and the incidence of new infections
have yet to be fully realized among all HIV-seropositive
groups, such as people who use illicit drugs. Crack co-
caine use has been shown to be an independent risk fac-
tor of HIV seroconversion in some settings, presumably
through high-risk sexual activities associated with crack
use [4–7]. While evidence-based strategies to reduce
HIV transmission risk through injection drug use exist,
such as needle and syringe programs [8], crack cocaine
is often smoked, and interventions to reduce sexual risk
behaviour among crack cocaine smokers have proven to
be of limited effectiveness [5, 9, 10].
In 2014, the Treatment-as-Prevention (TasP) approach,
which aims to expand access and adherence to HAART
among people living with HIV and thereby prevent HIV
transmission, was incorporated into the global HIV/
AIDS response strategies by the Joint United Nations
Programme on HIV/AIDS [11]. This is likely a
potentially effective HIV prevention approach to address
HIV transmission associated with persistent high-risk
behaviour among HIV-infected crack cocaine users [12].
However, there remains concern regarding the viability
of the intervention due to previous studies describing
sub-optimal adherence to HAART in crack cocaine
using populations [13–15]. For example, a 2002 study of
HIV-infected people who use drugs reported that the
strongest predictor of poor adherence to antiretroviral
medications was cocaine/crack cocaine use [13]. A more
recent study found that stimulant users, particularly
those who used cocaine/crack cocaine, had seven times
higher odds of HAART adherence failure (i.e., <90 % of
doses taken) compared to patients who did not use
drugs [15].
Despite many reports of poor adherence to HAART
among HIV-infected crack cocaine users [13–15], to
date, there is a paucity of research identifying factors as-
sociated with HAART adherence and plasma HIV RNA
viral load (pVL) suppression in this population, which
may be amenable to intervention. This is a concern as
the success of TasP-based approaches relies on ensuring
access and adherence to HAART. In this study, we
sought to identify correlates of optimal adherence to
antiretroviral medications and pVL non-detectability
among HAART-exposed crack cocaine users in Vancouver,
Canada, where crack cocaine use is common and has




Data for this analysis were derived from the AIDS Care
Cohort to evaluate Exposure to Survival Services
(ACCESS), a prospective cohort study of HIV-positive
people who use illicit drugs in Vancouver, Canada.
Recruitment and data collection procedures have been
described in detail elsewhere [16]. In brief, beginning in
1996, participants were recruited through self-referral and
street-based outreach from Vancouver’s Downtown
Eastside neighbourhood, a post-industrial area with a large
open drug market and high levels of illicit drug use,
poverty, and HIV infection. Individuals were eligible to
participate in ACCESS if they were aged 18 years or older,
were HIV-seropositive, had used illicit drugs other than
cannabis in the month prior to enrolment, and provided
written informed consent. Participants were compensated
$20 CAD at each study visit.
At baseline and semi-annually thereafter, participants
completed an interviewer-administered questionnaire
soliciting demographic data, information on drug use
patterns, as well as other characteristics and exposures.
At each visit, individuals also underwent an examination
by a study nurse and provided blood samples for sero-
logic analyses. Through a confidential linkage with the
provincial Drug Treatment Program (DTP), a complete
clinical profile of all CD4 T-cell counts, pVL observa-
tions, exposure to specific antiretroviral agents, and
treatment outcomes for each participant were obtained.
In British Columbia, all provision of HIV treatment is
centralized through a province-wide dispensation pro-
gram, where treatment and related care are provided
free of charge. Data collection by the DTP has been
described previously [17, 18]. The ACCESS study has
been approved by the University of British Columbia/
Providence Health Care Research Ethics Board.
Participants and measures
Participants were eligible for the present analysis if they
were recruited by ACCESS between December 1, 2005
and November 30, 2013, reported having smoked crack
cocaine in the six months prior to the baseline assess-
ment, and had initiated HAART prior to enrolment in
ACCESS. As well, at least one observation of CD4 cell
count and pVL had to be completed within ±180 days of
the day they entered the study. For a sub-analysis focus-
ing on dual crack cocaine and opioid users, the sample
was further restricted to those who had a history of any
opioid use or participation in methadone maintenance
therapy at baseline.
The primary outcomes of interest were optimal adher-
ence to pharmacy refills for antiretroviral medications and
pVL non-detectability in the previous six months. We
measured pharmacy refill adherence in each 6-month
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period as the number of days for which medications were
dispensed over the number of days since the initiation of
HAART, which was capped at 180 days. We defined opti-
mal pharmacy refill adherence as equal to or greater than
95 %. We have previously demonstrated the clinical valid-
ity of this pharmacy refill data and shown that it reliably
predicts virologic suppression [19, 20] and survival [21].
Plasma HIV RNA viral load non-detectability was defined
as having achieved a HIV RNA viral load of <50 copies/
mL of plasma. In the event that more than one pVL obser-
vation was made within a 6-month follow-up period, we
used the median of all the observations, which was then
categorized into either <50 or ≥50 copies/mL of plasma.
We considered a range of explanatory variables that
might be associated with optimal pharmacy refill adher-
ence and/or pVL non-detectability. Demographic char-
acteristics included: age (per 10-year older), gender
(male vs. female), ethnicity (Caucasian vs. other), and
education level (<secondary education vs. ≥secondary
education). Substance-using behaviours included: crack
cocaine smoking (≥daily vs. <daily), heroin use (≥daily
vs. <daily), crystal methamphetamine use (≥daily vs.
<daily), and heavy alcohol use (≥5 drinks per day vs. <5
drinks per day). Other behavioural variables included:
homelessness, engagement in sex work or drug dealing,
incarceration, participation in inpatient addiction treat-
ment (i.e., recovery houses, detoxification facilities, and
treatment centres), participation in outpatient detoxifica-
tion services, seeing drug counsellors or participation in
addiction-related peer support meetings (e.g., Narcotics
Anonymous, Cocaine Anonymous, etc.), and participa-
tion in opioid substitution therapies (i.e., methadone
maintenance therapy or Suboxone treatment) (all: yes vs.
no). The use of opioid substitution therapies was consid-
ered in the sub-analysis focusing on dual crack cocaine
and opioid users only. Clinical variables included: CD4
cell count (per 100-cells/mm3 increase); antiretroviral
tablet regimen (single tablet vs. 2-3 tablets vs. >3 tablets
per day); years since HAART initiation (per year in-
crease); physician experience on HIV care at the time of
antiretroviral therapy initiation (having ever treated <6
patients vs. ≥6 patients). All variables except for the
demographic characteristics referred to the previous six
months unless otherwise indicated.
Statistical analyses
First, we examined baseline characteristics of the sample,
stratified by medication adherence (≥95 % vs. <95 %) in
the six months prior to the baseline assessment.
Categorical variables were analysed using Pearson’s χ2
test (or Fisher’s exact test in the presence of small sell
counts) and continuous variables were analysed using
the Wilcoxon rank-sum test. Next, we used generalized
linear mixed-effects modelling (GLMM) with the logit
link to longitudinally identify factors associated with opti-
mal pharmacy refill adherence and pVL non-detectability,
respectively. This form of regression modelling accounts
for the correlation between repeated observations gath-
ered over time from the same individual, and estimates
the effect of the explanatory variables on the likeli-
hood of optimal pharmacy refill adherence and pVL
non-detectability in each individual.
Since our study aimed to identify the set of variables
that best explains a higher odds of optimal pharmacy re-
fill adherence and pVL non-detectability, respectively,
we used a priori-defined statistical protocol based on
the examination of the Akaike information criterion
(AIC) and Type III p-values to construct multivariable
GLMM logistic regression models. This procedure bal-
ances model selection on finding the best explanatory
model with best model fit, as described previously [22].
In brief, we first included in the full multivariable
models all explanatory variables that were significantly
associated with optimal pharmacy refill adherence and
pVL non-detectability, respectively, at the p < 0.10 level
in the univariable analyses. After examining the AIC
value of the models, we removed the variable with the
largest p-value and built a reduced model. We continued
this iterative process and selected the multivariable
models with the lowest AIC value. Through this process,
some variables, even though being significantly associ-
ated with an outcome at the level of p < 0.05 in bivari-
able analyses, were dropped from the final multivariable
model. For the sub-analysis focusing on dual crack co-
caine and opioid users, we added participation in opioid
substitution therapies to the final multivariable models
as a covariate. All p-values were two-sided. All statistical
analyses were performed using the SAS software version
9.3 (SAS, Cary, NC).
Results
In total, 438 HAART-exposed crack cocaine users were
included in this study, of whom 293 (66.9 %) were male
and 239 (54.6 %) self-reported Caucasian ancestry. Of
the 438 participants, 406 (92.7 %) had returned for at
least one follow-up visit, contributing a median follow-
up duration of 48.0 months (interquartile range [IQR]:
35.0 – 75.9). At baseline, 240 (54.8 %) exhibited optimal
pharmacy refill adherence in the previous six months,
and a total of 390 (89.0 %) individuals attained optimal
adherence at some point during the study period.
Table 1 presents sample characteristics at baseline,
stratified by medication adherence levels. A substantial
proportion of the sample was homeless (29.5 %), smoked
crack cocaine at least on a daily basis (40.0 %), and en-
gaged in sex work or drug dealing (37.4 %) in the previ-
ous six months. Very few individuals accessed any types
of addiction treatment except for opioid substitution
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Table 1 Baseline characteristics of HAART-exposed crack cocaine users in Vancouver, Canada, stratified by optimal pharmacy refill









Age (median, IQR) 44 (38–49) 45 (40–51) 42 (37–46) <0.001
Gender
Male 293 (66.9 %) 171 (71.3 %) 122 (61.6 %) 0.033
Female 145 (33.1 %) 69 (28.7 %) 76 (38.4 %) reference
Ancestry
Caucasian 239 (54.6 %) 147 (61.3 %) 92 (46.5 %) 0.002
Non-Caucasian 199 (45.4 %) 93 (38.7 %) 106 (53.5 %) reference
Education
< Secondary education 228 (52.1 %) 116 (48.3 %) 112 (56.6 %) 0.069
≥ Secondary education 196 (44.7 %) 117 (48.8 %) 79 (39.9 %) reference
Homelessa
Yes 129 (29.5 %) 57 (23.8 %) 72 (36.4 %) 0.003
No 306 (69.9 %) 182 (75.8 %) 124 (62.6 %) reference
Crack cocaine smokinga
≥ Daily 175 (40.0 %) 78 (32.5 %) 97 (49.0 %) 0.001
< Daily 263 (60.0 %) 162 (67.5 %) 101 (51.0 %) reference
Heroin usea
≥ Daily 48 (11.0 %) 19 (7.9 %) 29 (14.7 %) 0.024
< Daily 389 (88.8 %) 221 (92.1 %) 168 (84.9 %) reference
Crystal methamphetamine usea,c
≥ Daily 9 (2.1 %) 5 (2.1 %) 4 (2.0 %) 1.000
< Daily 428 (97.7 %) 235 (97.9 %) 193 (97.5 %) reference
Heavy alcohol use (≥5 drinks per day)a,c
Yes 13 (3.0 %) 5 (2.1 %) 8 (4.0 %) 0.266
No 425 (97.0 %) 235 (97.9 %) 190 (96.0 %) reference
Engagement in sex work or drug dealinga
Yes 164 (37.4 %) 78 (32.5 %) 86 (43.4 %) 0.018
No 270 (61.6 %) 160 (66.7 %) 110 (55.6 %) reference
Incarcerationa
Yes 58 (13.2 %) 32 (13.3 %) 26 (13.1 %) 0.951
No 380 (86.8 %) 208 (86.7 %) 172 (86.9 %) reference
HIV physician experienceb
Previously treated <6 patients 48 (11.0 %) 25 (10.4 %) 23 (11.6 %) 0.397
Previously treated ≥6 patients 340 (77.6 %) 199 (82.9 %) 141 (71.2 %) reference
CD4 cell counta (median, IQR) 300 (180–450) 340 (223.5–495) 235 (120–360) <0.001
Years since HAART initiationa (median, IQR) 5.7 (2.2–8.5) 4.9 (1.6–8.0) 6.9 (3.2–8.8) <0.001
Regimenb
Single tablet per day 34 (7.8 %) 24 (10.0 %) 10 (5.1 %) 0.278
2-3 tablets per day 121 (27.6 %) 76 (31.7 %) 45 (22.7 %) 0.723
> 3 tablets per day 230 (52.5 %) 140 (58.3 %) 90 (45.5 %) reference
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therapies (1.1–9.8 %), while the majority (63.5 %) of 293
dual crack cocaine and opioid users participated in opi-
oid substitution therapies in the previous six months.
Compared to those who had suboptimal pharmacy re-
fill adherence in the previous six months, individuals
who had optimal pharmacy refill adherence were older,
more likely to be male, self-report Caucasian ancestry,
possess a high school diploma, have higher CD4 cell
count and a shorter length of exposure to HAART, and
have seen drug counsellors or participated in addiction-
related peer support groups in the previous six months,
while they were less likely to be homeless, smoke crack
cocaine or use heroin at least daily, engage in sex work
or drug dealing in the previous six months (all p < 0.05).
Additionally, among a sub-sample of dual crack cocaine
and opioid users, those who accessed opioid substitution
therapies were more likely to have exhibited optimal
pharmacy refill adherence (p = 0.005). Table 2 presents
baseline characteristics stratified by pVL non-detectability.
The observed significant associations were generally simi-
lar to those found with optimal pharmacy refill adherence,
except that those who were on a 2-3 tablet-per-day
regimen were more likely to have pVL non-detectability
compared to those who were on a >3 tablet-per-day regi-
men (p = 0.008).
Table 3 shows the results of univariable and multivari-
able GLMM logistic regression analyses of factors asso-
ciated with optimal pharmacy refill adherence. As
shown, in univariable analyses, older age (odds ratio
[OR]: 2.29; 95 % confidence interval [CI]: 1.84 – 2.86),
male gender (OR: 1.50; 95 % CI: 1.02 – 2.20), Caucasian
ethnicity (OR: 1.61; 95 % CI: 1.12 – 2.32), higher CD4
count (OR: 1.39; 95 % CI: 1.30 – 1.48) and longer history
of HAART (OR: 1.08; 95 % CI: 1.04 – 1.12) were signifi-
cantly and positively associated with optimal pharmacy
refill adherence. Homelessness (OR: 0.44; 95 % CI: 0.34 –
0.58), at least daily crack cocaine smoking (OR: 0.49; 95 %
CI: 0.39 – 0.62), at least daily heroin use (OR: 0.32; 95 %
CI: 0.22 – 0.47), and engagement in sex work or drug
dealing (OR: 0.59; 95 % CI: 0.47 – 0.76) were significantly
and negatively associated with optimal pharmacy refill
adherence.
In the final multivariable model, older age (adjusted
odds ratio [AOR]: 1.65; 95 % CI: 1.33 – 2.04) and higher
CD4 count (AOR: 1.31; 95 % CI: 1.23 – 1.41) remained
independently and positively associated with optimal
pharmacy refill adherence, while homelessness (AOR:
0.58; 95 % CI: 0.44 – 0.77), at least daily crack cocaine
smoking (AOR: 0.64; 95 % CI: 0.50 – 0.81), and at least
daily heroin use (AOR: 0.43; 95 % CI: 0.29 – 0.65)
remained independently and negatively associated with
optimal pharmacy refill adherence. When the sample
was restricted to dual crack cocaine and opioid users,
the same set of variables remained significantly associ-
ated with optimal pharmacy refill adherence. Participa-
tion in opioid substitution therapies was not
independently associated with optimal pharmacy refill
adherence (AOR: 1.39; 95 % CI: 0.99 – 1.96).
Table 4 presents the results univariable and multivari-
able GLMM logistic regression analyses of factors asso-
ciated with pVL non-detectability. As shown, in addition
to the covariates that were included for medication
adherence, the final multivariable models included
years since HAART initiation and antiretroviral tablet
Table 1 Baseline characteristics of HAART-exposed crack cocaine users in Vancouver, Canada, stratified by optimal pharmacy refill
adherence (n = 438) (Continued)
Participation in inpatient addiction treatmenta
Yes 35 (8.0 %) 19 (7.9 %) 16 (8.1 %) 0.950
No 403 (92.0 %) 221 (92.1 %) 182 (91.9 %) reference
Participation in outpatient detoxification or other outpatient addiction treatmenta,c
Yes 5 (1.1 %) 4 (1.7 %) 1 (0.5 %) 0.384
No 433 (98.9 %) 236 (98.3 %) 197 (99.5 %) reference
Seeing drug counsellors or participation in addiction-related peer support meetingsa
Yes 43 (9.8 %) 31 (12.9 %) 12 (6.1 %) 0.016
No 395 (90.2 %) 209 (87.1 %) 186 (93.9 %) reference
Restricted to dual crack cocaine and opioid users (n = 293)
Participation in opioid substitution therapiesa
Yes 186 (63.5 %) 115 (70.6 %) 71 (54.6 %) 0.005
No 107 (36.5 %) 48 (29.4 %) 59 (45.4 %) reference
HAART highly active antiretroviral therapy, CI confidence interval, IQR interquartile range
a denotes activities/events in the past 6 months
b denotes at the time of antiretroviral therapy initiation
c p-values were derived from Fisher’s exact test
Not all cells added up to 100 % due to some missing values
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Age (median, IQR) 44 (38–49) 45 (41–51) 42 (36–47) <0.001
Gender
Male 293 (66.9 %) 149 (70.3 %) 144 (63.7 %) 0.145
Female 145 (33.1 %) 63 (29.7 %) 82 (36.3 %) reference
Ancestry
Caucasian 239 (54.6 %) 122 (57.5 %) 117 (51.8 %) 0.225
Non-Caucasian 199 (45.4 %) 90 (42.5 %) 109 (48.2 %) reference
Education
< Secondary education 228 (52.1 %) 107 (50.5 %) 121 (53.5 %) 0.462
≥ Secondary education 196 (44.7 %) 99 (46.7 %) 97 (42.9 %) reference
Homelessa
Yes 129 (29.5 %) 36 (17.0 %) 93 (41.2 %) <0.001
No 306 (69.9 %) 174 (82.1 %) 132 (58.4 %) reference
Crack cocaine smokinga
≥ Daily 175 (40.0 %) 72 (34.0 %) 103 (45.6 %) 0.013
< Daily 263 (60.0 %) 140 (66.0 %) 123 (54.4 %) reference
Heroin usea
≥ Daily 48 (11.0 %) 16 (7.5 %) 32 (14.2 %) 0.026
< Daily 389 (88.8 %) 196 (92.5 %) 193 (85.4 %) reference
Crystal methamphetamine usea,c
≥ Daily 9 (2.1 %) 6 (2.8 %) 3 (1.3 %) 0.326
< Daily 428 (97.7 %) 206 (97.2 %) 222 (98.2 %) reference
Heavy alcohol use (≥5 drinks per day)a,c
Yes 13 (3.0 %) 4 (1.9 %) 9 (4.0 %) 0.263
No 425 (97.0 %) 208 (98.1 %) 217 (96.0 %) reference
Engagement in sex work or drug dealinga
Yes 164 (37.4 %) 72 (34.0 %) 92 (40.7 %) 0.145
No 270 (61.6 %) 138 (65.1 %) 132 (58.4 %) reference
Incarcerationa
Yes 58 (13.2 %) 25 (11.8 %) 33 (14.6 %) 0.386
No 380 (86.8 %) 187 (88.2 %) 193 (85.4 %) reference
HIV physician experienceb
Previously treated <6 patients 48 (11.0 %) 21 (9.9 %) 27 (11.9 %) 0.418
Previously treated ≥6 patients 340 (77.6 %) 170 (80.2 %) 170 (75.2 %) reference
CD4 cell counta (median, IQR) 300 (180–450) 360 (260–500) 230 (110–360) <0.001
Years since HAART initiationa (median, IQR) 5.7 (2.2–8.5) 5.9 (2.3–8.7) 5.5 (2.1–8.4) 0.243
Regimenb
Single tablet per day 34 (7.8 %) 18 (8.5 %) 16 (7.1 %) 0.713
2-3 tablets per day 121 (27.6 %) 78 (36.8 %) 43 (19.0 %) 0.008
> 3 tablets per day 230 (52.5 %) 114 (53.8 %) 116 (51.3 %) reference
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regimen. Longer history of HAART (AOR: 1.06; 95 %
CI: 1.01 – 1.12) and receiving a single tablet-per-day
regimen (AOR: 3.02; 95 % CI: 1.67 – 5.46) were inde-
pendently and positively associated with pVL non-
detectability. The results for the other covariates were
consistent with those found in the multivariable
model of medication adherence except that among
dual crack cocaine and opioid users, participation in
opioid substitution therapies was independently and
positively associated with pVL non-detectability
(AOR: 1.55; 95 % CI: 1.02 – 2.34).
Discussion
Among our sample of HAART-exposed crack cocaine
users, we found that homelessness, and high-intensity
crack cocaine and heroin use were independently and
negatively associated with optimal pharmacy refill adher-
ence and pVL non-detectability. Except for opioid sub-
stitution therapies, none of the addiction treatment
modalities assessed, including inpatient treatment, out-
patient detoxification services, drug counselling, and
participation in peer support groups such as Narcotics
Anonymous, were significantly associated with optimal
pharmacy refill adherence or pVL non-detectability. Spe-
cifically among a sub-sample of dual crack cocaine and
opioid users, enrolment in opioid substitution therapies
was independently associated with pVL non-detectability
but not with optimal pharmacy refill adherence.
We found an independent association between at least
daily use of crack cocaine and poor medication adher-
ence and having a detectable viral load. This is consist-
ent with previous reports that crack cocaine users are
less likely to enjoy gains from HAART [13–15]. In
addition, the finding that at least daily use of heroin was
also independently associated with suboptimal pharmacy
refill adherence and outcome indicates a need to address
poly-substance use among HIV-infected crack cocaine
users. Previous research suggested that poly-substance
use is quite common among people who use drugs, al-
though those who primarily use cocaine may continue
to use it consistently over an extended period of time
while keeping the use of other non-primary drugs at
relatively lower levels [23]. While current literature sug-
gests no clinically significant pharmacokinetic interac-
tions between crack cocaine and antiretroviral agents,
methamphetamines may have possible lethal interactions
with antiretroviral agents that inhibit the CYP450 system
[24]. In our sample of HIV-positive crack cocaine users,
high-intensity use of crystal methamphetamine was not
common or associated with optimal pharmacy refill ad-
herence or pVL non-detectability; however, in a setting
where co-use of crack cocaine and crystal methampheta-
mine is common, a greater caution is required when pre-
scribing HAART. Collectively, these findings emphasize
the need to ensure that a variety of addiction treatment
options be integrated with HIV treatment and care for in-
dividuals who use crack cocaine.
The finding that none of the addiction treatment mo-
dalities except for opioid substitution therapies were as-
sociated with optimal pharmacy refill adherence or viral
suppression serves to underscore previous calls for iden-
tifying more evidence-based addiction treatment ap-
proaches that also confer benefits on HIV disease
management among HIV-positive crack cocaine users
Table 2 Baseline characteristics of HAART-exposed crack cocaine users in Vancouver, Canada, stratified by pVL non-detectability (n= 438)
(Continued)
Participation in inpatient addiction treatmenta
Yes 35 (8.0 %) 14 (6.6 %) 21 (9.3 %) 0.300
No 403 (92.0 %) 198 (93.4 %) 205 (90.7 %) reference
Participation in outpatient detoxification or other outpatient addiction treatmenta,c
Yes 5 (1.1 %) 4 (1.9 %) 1 (0.4 %) 0.203
No 433 (98.9 %) 208 (98.1 %) 225 (99.6 %) reference
Seeing drug counsellors or participation in addiction-related peer support meetingsa
Yes 43 (9.8 %) 30 (14.2 %) 13 (5.8 %) 0.003
No 395 (90.2 %) 182 (85.8 %) 213 (94.2 %) reference
Restricted to dual crack cocaine and opioid users (n = 293)
Participation in opioid substitution therapiesa
Yes 186 (63.5 %) 98 (72.6 %) 88 (55.7 %) 0.003
No 107 (36.5 %) 37 (29.4 %) 70 (45.4 %) reference
HAART highly active antiretroviral therapy, CI confidence interval, IQR interquartile range, pVL plasma HIV RNA viral load
a denotes activities/events in the past 6 months
b denotes at the time of antiretroviral therapy initiation
c p-values were derived from Fisher’s exact test
Not all cells added up to 100 % due to some missing values
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Table 3 Univariable and multivariable GLMM logistic regression analyses of factors associated with optimal pharmacy refill
adherence for antiretroviral medications among HAART-exposed crack cocaine users in Vancouver, Canada, 2005–2013
Characteristic Total sample of crack cocaine users
(n = 438)












(per 10-year older) 2.29 (1.84 – 2.86) <0.001 1.65 (1.33 – 2.04) <0.001 2.75 (2.06 – 3.68) <0.001 1.72 (1.30 – 2.26) <0.001
Gender
(male vs. female) 1.50 (1.02 – 2.20) 0.041 1.10 (0.68 – 1.79) 0.696
Ethnicity
(Caucasian vs. other) 1.61 (1.12 – 2.32) 0.011 1.40 (0.87 – 2.24) 0.167
Education
(<secondary vs. ≥secondary) 0.83 (0.57 – 1.20) 0.327 0.98 (0.61 – 1.58) 0.943
Homelessa,b
(yes vs. no) 0.44 (0.34 – 0.58) <0.001 0.58 (0.44 – 0.77) <0.001 0.39 (0.28 – 0.54) <0.001 0.56 (0.40 – 0.79) <0.001
Crack cocaine smokinga,b
(≥daily vs. <daily) 0.49 (0.39 – 0.62) <0.001 0.64 (0.50 – 0.81) <0.001 0.41 (0.31 – 0.55) <0.001 0.57 (0.43 – 0.75) <0.001
Heroin usea,b
(≥daily vs. <daily) 0.32 (0.22 – 0.47) <0.001 0.43 (0.29 – 0.65) <0.001 0.30 (0.20 – 0.46) <0.001 0.45 (0.29 – 0.70) <0.001
Crystal methamphetamine usea,b
(≥daily vs. <daily) 1.07 (0.50 – 2.30) 0.858 0.79 (0.32 – 1.94) 0.609
Heavy alcohol usea,b
(≥5 drinks per day vs. <5 drinks
per day)
1.17 (0.65 – 2.10) 0.596 1.37 (0.60 – 3.10) 0.452
Engagement in sex work or drug dealinga,b
(yes vs. no) 0.59 (0.47 – 0.76) <0.001 0.54 (0.41 – 0.71) <0.001
Incarcerationa,b
(yes vs. no) 0.71 (0.49 – 1.02) 0.063 0.63 (0.41 – 0.96) 0.031
HIV physician experiencec
(<6 patients vs. ≥6 patients) 0.74 (0.40 – 1.35) 0.322 0.60 (0.29 – 1.24) 0.169
CD4 cell counta,b
(per 100-cell increase) 1.39 (1.30 – 1.48) <0.001 1.31 (1.23 – 1.41) <0.001 1.43 (1.32 – 1.55) <0.001 1.34 (1.23 – 1.45) <0.001
Years since HAART initiationa,b
(per year increase) 1.08 (1.04 – 1.12) <0.001 1.11 (1.06 – 1.16) <0.001
Regimena,b
(1 pill per day vs. >3 pills per day) 1.23 (0.80 – 1.90) 0.339 1.29 (0.76 – 2.19) 0.347
(2-3 pills per day vs. >3 pills per day) 1.01 (0.79 – 1.30) 0.920 1.07 (0.78 – 1.48) 0.659
Participation in inpatient addiction treatmenta,b
(yes vs. no) 0.82 (0.57 – 1.18) 0.294 0.84 (0.54 – 1.32) 0.454
Participation in outpatient detoxification or other outpatient addiction treatmenta,b
(yes vs. no) 0.65 (0.20 – 2.09) 0.472 0.43 (0.09 – 2.02) 0.284
Hayashi et al. BMC Infectious Diseases  (2016) 16:455 Page 8 of 12
[5, 14, 25]. While a previous pilot study suggested that a
video-based behavioural intervention employing the
Information-Motivation-Behavioural Skill model might
be efficacious in reducing crack cocaine use and improv-
ing medication adherence among HIV-positive crack co-
caine users [26], the efficacy of the intervention needs to
be determined with a larger sample. Also, the long-term
post-intervention effect on crack cocaine use and medi-
cation adherence is an important outcome to be exam-
ined, as a Cochrane Collaboration systematic review has
reported that many behavioural interventions for sub-
stance use suffer from a lack of the sustained effect fol-
lowing the intervention [27]. Further, unlike the case of
opiate addiction, there is currently no approved medica-
tion to treat crack cocaine addiction. While many candi-
date medications have been evaluated for the efficacy in
the treatment of crack cocaine/cocaine addiction during
the past decade, overall results have been inconclusive
[28–30]. Further research is needed in this area.
In contrast, we found that dual crack cocaine and opi-
oid users who were enrolled in opioid substitution ther-
apies were more likely to achieve virological success, and
the positive effect of opioid substitution therapies
remained significant even after the adjustment for the
high-intensity use of crack cocaine and heroin. This adds
important evidence to a body of research indicating the
effectiveness of these therapies for the improvement of
HIV treatment adherence and outcomes [31]. Previous
studies reported that ongoing cocaine use undermined
the effectiveness of opioid substitution therapies for HIV
treatment-related outcomes among HIV-infected pa-
tients accessing these therapies [32, 33]. However, our
findings suggest that opioid substitution therapies still
help HIV-infected dual crack cocaine and opioid users
achieve optimal HAART outcomes. Nonetheless, as
crack cocaine/cocaine users have been shown to have
significant barriers to adherence and continuance of opi-
oid substitution therapies [34, 35], adjunct interventions
to opioid substitution therapies that help retain crack
cocaine/cocaine-using patients in treatment need to be
developed.
Similarly to our previous investigation that indicated
that homelessness posed a barrier to antiretroviral
therapy among HIV-infected people who use illicit drugs
generally [36], we found that homelessness was
independently associated with suboptimal pharmacy re-
fill adherence and viral suppression failures among HIV-
infected individuals who use crack cocaine in a setting
where HAART is provided free of charge. Collectively,
these findings indicate that, in addition to identification
of evidence-based addiction treatment strategies for
crack cocaine use, structural interventions to address
homelessness in general (e.g., housing assistance) are
needed. Expanding and promoting support services for
HIV-positive homeless individuals focusing on both ac-
cess and adherence to HAART would maximise the ben-
efits of HAART on disease progression and onward viral
transmission in this population.
Our study has several limitations. First, as the study
sample was not randomly selected, our findings may not
be generalizable to other populations of crack cocaine
users. Second, the self-reported data may be affected by
reporting biases, including recall bias and socially desir-
able responding. However, we note that this type of data
has been commonly utilized in observational studies in-
volving people who use drugs and found to be valid [37].
Also, as our primary outcomes were ascertained through
a confidential record linkage to the provincial HIV-
related clinical database, we believe that it is unlikely
that potential reporting biases have impacted the data
differentially by the medication adherence or pVL levels.
Third, as with all observational studies, the relationships
between the explanatory variables and outcome assessed
may be under the influence of unobserved confounding,
although we sought to address this bias with multivari-
able adjustment of the key demographic, behavioural,
and clinical predictors of medication adherence or viral
suppression.
Conclusions
In sum, among our sample of HAART-exposed crack
cocaine users, those who were homeless and those who
engaged in high-intensity crack cocaine or heroin use
were more likely to have suboptimal adherence to anti-
retroviral medications and fail to achieve viral suppres-
sion. Further, none of the addiction treatment modalities
Table 3 Univariable and multivariable GLMM logistic regression analyses of factors associated with optimal pharmacy refill
adherence for antiretroviral medications among HAART-exposed crack cocaine users in Vancouver, Canada, 2005–2013 (Continued)
Seeing drug counsellors or participation in addiction-related peer support meetingsa,b
(yes vs. no) 1.06 (0.76 – 1.48) 0.730 0.84 (0.55 – 1.28) 0.424
Participation in opioid substitution therapiesa,b
(yes vs. no) ––– ––– 1.71 (1.23 – 2.38) 0.001 1.39 (0.99 – 1.96) 0.056
GLMM generalized linear mixed-effect modelling, HAART highly active antiretroviral therapy, OR odds ratio, CI confidence interval
a denotes activities/events in the past 6 months
b denotes time-varying variables
c denotes at the time of antiretroviral therapy initiation
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Table 4 Univariable and multivariable GLMM logistic regression analyses of factors associated with pVL non-detectability among
HAART-exposed crack cocaine users in Vancouver, Canada, 2005–2013
Characteristic Total sample of crack cocaine users
(n = 438)












(per 10-year older) 5.24 (3.72 – 7.37) <0.001 1.86 (1.37 – 2.52) <0.001 5.22 (3.45 – 7.89) <0.001 1.59 (1.11 – 2.26) 0.011
Gender
(male vs. female) 1.86 (1.10 – 3.15) 0.020 1.08 (0.59 – 1.97) 0.804
Ethnicity
(Caucasian vs. other) 1.31 (0.79 – 2.17) 0.290 1.38 (0.77 – 2.49) 0.282
Education
(<secondary vs. ≥secondary) 1.03 (0.62 – 1.72) 0.909 1.39 (0.77 – 2.49) 0.272
Homelessa,b
(yes vs. no) 0.26 (0.19 – 0.36) <0.001 0.39 (0.28 – 0.54) <0.001 0.24 (0.17 – 0.35) <0.001 0.37 (0.25 – 0.56) <0.001
Crack cocaine smokinga,b
(≥daily vs. <daily) 0.47 (0.36 – 0.61) <0.001 0.39 (0.29 – 0.53) <0.001 0.69 (0.49 – 0.96) 0.028
Heroin usea,b
(≥daily vs. <daily) 0.35 (0.23 – 0.54) <0.001 0.60 (0.36 – 0.98) 0.042 0.32 (0.20 – 0.51) <0.001
Crystal methamphetamine usea,b
(≥daily vs. <daily) 1.09 (0.45 – 2.62) 0.853 1.15 (0.43 – 3.10) 0.779
Heavy alcohol usea,b
(≥5 drinks per day vs. <5 drinks
per day)
0.70 (0.36 – 1.37) 0.302 0.57 (0.24 – 1.37) 0.209
Engagement in sex work or drug dealinga,b
(yes vs. no) 0.58 (0.44 – 0.75) <0.001 0.58 (0.43 – 0.78) <0.001
Incarcerationa,b
(yes vs. no) 0.57 (0.38 – 0.86) 0.008 0.49 (0.31 – 0.78) 0.002
HIV physician experiencec
(<6 patients vs. ≥6 patients) 1.15 (0.51 – 2.62) 0.738 0.84 (0.35 – 2.00) 0.688
CD4 cell counta,b
(per 100-cell increase) 1.93 (1.76 – 2.13) <0.001 1.67 (1.52 – 1.83) <0.001 1.98 (1.77 – 2.21) <0.001 1.72 (1.54 – 1.91) <0.001
Years since HAART initiationa,b
(per year increase) 1.27 (1.21 – 1.34) <0.001 1.06 (1.01 – 1.12) 0.012 1.29 (1.22 – 1.37) <0.001 1.08 (1.02 – 1.14) 0.011
Regimena,b
(1 pill per day vs. >3 pills per day) 3.11 (1.76 – 5.52) <0.001 3.02 (1.67 – 5.46) <0.001 2.84 (1.45 – 5.57) 0.003 2.60 (1.30 – 5.21) 0.007
(2-3 pills per day vs. >3 pills per day) 1.70 (1.27 – 2.30) <0.001 1.24 (0.91 – 1.69) 0.179 1.60 (1.13 – 2.29) 0.009 1.14 (0.79 – 1.65) 0.493
Participation in inpatient addiction treatmenta,b
(yes vs. no) 0.67 (0.45 – 1.02) 0.061 0.58 (0.35 – 0.97) 0.037
Participation in outpatient detoxification or other outpatient addiction treatmenta,b
(yes vs. no) 1.10 (0.33 – 3.71) 0.872 1.63 (0.34 – 7.74) 0.539
Seeing drug counsellors or participation in addiction-related peer support meetingsa,b
(yes vs. no) 1.32 (0.90 – 1.94) 0.158 1.16 (0.73 – 1.84) 0.532
Participation in opioid substitution therapiesa,b
(yes vs. no) ––– ––– 2.28 (1.58 – 3.30) <0.001 1.55 (1.02 – 2.34) 0.039
GLMM generalized linear mixed-effect modelling, pVL plasma HIV RNA viral load, HAART highly active antiretroviral therapy, OR odds ratio, CI confidence interval
a denotes activities/events in the past 6 months
b denotes time-varying variables
c denotes at the time of antiretroviral therapy initiation
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assessed appeared to facilitate medication adherence or
viral suppression, except for opioid substitution therap-
ies. These findings suggest an urgent need to develop
evidence-based treatment options for crack cocaine use
that also confer benefits to HAART-related outcomes.
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